休活动干预轻度认知障碍患者的认知:一个元分析
Xueming He1, Chuming Liu2, Zhaoyang Li2
1Heilongjiang Academy of Chinese Medicine, Harbin, Heilongjiang, 150036, People's Republic of China.
Neuropsychiatric disease and treatment
|August 19, 2025
概括
休活动显著改善认知功能和认知障碍患者的记忆力. 这些有吸引力的活动为传统的认知康复培训提供了可行的替代方案或补充.
科学领域:
- 老年学是一门学科.
- 神经康复疗法 神经康复疗法
- 认知科学 认知科学
背景情况:
- 认知障碍是影响老年人的日益严重的社会问题.
- 传统的认知康复培训 (TCRT) 面临着可访问性限制.
- 休活动显示了认知康复的潜力,但缺乏具体证据.
研究的目的:
- 评估休活动干预措施与TCRT相比对认知障碍的有效性.
- 综合来自随机对照试验关于休活动对认知的影响的证据.
主要方法:
- 截至2024年12月10日的20项随机对照试验 (n=1126) 的元分析.
- 在PubMed,Embase,Cochrane受控试验注册表上进行的搜索.
- 使用PEDro规模评估偏见风险;干预措施包括麻将,克和VR等游戏.
主要成果:
- 休活动显著改善了整体认知功能 (MOCA,MMSE).
- 记忆功能显示显著改善 (DSB,DSF).
- 休活动对生活质量 (ADL) 有积极的影响.
结论:
- 休活动是对认知障碍的有效补充疗法.
- 这些活动增强了特定的认知领域和整体幸福感.
- 休干预提供了认知康复的实用方法.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
Cognitive Development During Adulthood
267
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
267
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260


